The compound increases resting energy expenditure and promotes fat oxidation around the clock
In this Analysis, we searched for relevant literature on the effects of GLP-1RAs across a range of illnesses, gathering and describing the available pre-clinical and mechanistic (278 studies) and clinical (96 studies) evidence for cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, eating disorders, and others
Mitch Biermann, MD, PhD, is an obesity and internal medicine specialist at Scripps Health.
The widely repeated claim that it is ~ten-million-fold more potent than BDNF is a relative in-vitro spine-counting ratio, not a human effect, and key mechanism papers from the originating lab were retracted in 2025
Can you qualify for a GLP-1 without diabetes
Liu WM, Dalgleish AG